UBS Maintains Neutral on Calumet, Raises Price Target to $47
Benzinga Newsdesk 2 months ago
NewsPrice TargetAnalyst Ratings
UBS analyst Manav Gupta maintains Calumet (NASDAQ:CLMT) with a Neutral and raises the price target from $26 to $47.
UBS analyst Manav Gupta maintains Calumet (NASDAQ:CLMT) with a Neutral and raises the price target from $26 to $47.